Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 133

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 8
Chunk 133
---
 unit entitles
to one vote.

Under the terms of the agreement,
Radiopharm Ventures’ purpose is to develop and commercialize diagnostic and therapeutic antibody-based products using the intellectual
property licensed by MD Anderson under the Technology Commercialization Agreement executed in September 2022. The Board Regents of The
University of Texas System, although not a member of Radiopharm Ventures, has the right to block any corporate action resulting in the
amendment of the Limited Liability Company Agreement, the issuance of units in Radiopharm Ventures, the admission of any new member, and
any actions beyond the scope of Radiopharm Ventures’ primary purpose including but not limited to acquisition of equity interests
in other entities, making loans to any person, settlement of claims against Radiopharm Ventures, and the execution of any agreement between
Radiopharm Ventures and Radiopharm and its affiliates.

In August 2024, Radiopharm
USA and MD Anderson agreed to amend the Limited Liability Company Agreement to increase Radiopharm USA’s interest in Radiopharm
Ventures. In particular, Radiopharm USA increased its ownership to 75% of the units issued by Radiopharm Ventures. Radiopharm USA will
pay an additional US$4 million to increase its ownership in Radiopharm Ventures.

Purchase and Development Agreement with Lantheus Holdings

In May 2024, we entered into
a Purchase and Development Agreement with Lantheus Holdings. Under the agreement, we sold to Lantheus Holdings (i) the rights to the DUNP19
clinical assets and any data and information regarding the compounds and other technology related to such asset arising from the Exclusive
License Agreement, dated March 22, 2022, with The Regents of the University of California and any data and information regarding the compounds
and other technology related to such asset, and (ii) the rights to the license regarding the TROP2 clinical asset arising from the Exclusive
License Agreement, July 9, 2021, with NanoMab Technology Limited and any data and information regarding the compounds and other technology
related to such asset.

Under the terms of the agreement,
Lantheus Holdings paid US$2 million for the assignment of the rights and licenses. In addition, Lantheus Holdings shall assume the liabilities
due under the assigned licenses.

The assignment of the licenses
and rights under such agreement will require Radiopharm to amend the clinical asset arising from the Exclusive License Agreement, July
9, 2021, with